CDMO honored as an exceptionally managed company
- Long-term strategy program propels company into a stable future
- Pioneer in sustainability along the entire value chain
- Holistic innovation management established
RAVENSBURG, Germany, May 30, 2023 / B3C newswire / -- Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has been recognized as Best Managed Company for the fourth time in a row – and now carries gold status. The internationally renowned award is presented annually by Deloitte Private, Frankfurter Allgemeine Newspaper and the Federation of German Industries (BDI) to medium-sized and family-run companies in over 40 countries.
"We are very proud to have been awarded this prestigious seal of quality for the fourth time," says Vetter Managing Director Peter Soelkner. "As a leading service provider in the production of complex injectable drugs, we are an innovative and reliable partner for our large and small customers – especially in economically challenging times. We see this award as a further confirmation that we are on the right track."
Earning this recognition requires a comprehensive and sustainable strategy. This is Vetter NExT 2029: six initiatives with 26 fields of action and four focus topics worked on by interdisciplinary teams with progress tracked regularly. The entire value chain of the CDMO is strategically covered. Higher-level topics of modern business operations are also addressed, such as digital transformation, organizational development, and sustainability.
Pioneer in sustainability
The judges also set high standards for the sustainability assessment. As one of the leading companies in the highly regulated and energy-intensive biopharma industry, Vetter has already been CO2-neutral worldwide since 2021. Last year, the CDMO published its first comprehensive sustainability report and achieved gold status in the internationally recognized EcoVadis ranking. At the beginning of this year, Vetter joined the UN Global Compact and is thus driving the expansion of responsible supply chains in the industry and sustainable business processes. The sustainability activities are an integral part of the corporate strategy and cover the areas of economy, ecology, and social issues.
Holistic innovation management for future technologies
An integral part of the corporate strategy is the innovation management process, through which trends are recognized at an early stage and converted into innovations in a targeted manner. The focus lays on sustainable technologies, processes, products, and services. One example is the optimization of production-related processes using new intelligent technologies.
"We continue to develop topic areas in line with customer demands, such as the interaction of man and machine in assistance systems or the use of cooperative and autonomous robots. These initiatives are compelling and at the same time essential in order to offer our customers innovative solutions, and consequently being able to partner at eye level," explains Vetter Managing Director Thomas Otto. The goal is to continuously improve flexibility, productivity, quality, IT, and operational safety.
Markus Seiz, Program Manager Best Managed Company and Director at Deloitte Private, explains the judge’s assessment as follows: "In all social crises, we look at the resilience and stability of the participating candidates. As a family-owned company, Vetter offers these success factors to a high degree, among others through its forward-looking and holistic strategic planning. In addition, the pharmaceutical service provider is already a leader in key transformation topics such as sustainability. These fields of action ensure future viability, resulting in Vetter being 'Best in Class' for us again this year."
Vetter Managing Director Peter Soelkner together with Dr Christine Wolter, Managing Partner Business Tax & International Tax Deloitte (right), and moderator Susanne Schoene (left) at the presentation of the Best Managed Companies Award on 25 May in Düsseldorf. © Vetter Pharma International GmbH:
For high resolution please click the image.
Find the Vetter press kit and more background information here.
About the Best Managed Companies Award
The Best Managed Companies Award recognizes the outstanding achievements and successes of private companies in more than 40 countries and honors the winners for their entrepreneurial spirit. In this context, each company's performance is analyzed in the key categories of Strategy, Productivity and Innovation, Culture and Engagement, and Finance and Governance, and judged by an independent panel of senior business, academic and media representatives.
About Vetter
Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 6,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early-stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at https://www.vetter-pharma.com.
Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
+49 (0)751-3700-3729
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Awards and Prizes; Drug Development; Clinical Trials as Topic; Pharmaceutical Services; Biotechnology; Pharmaceutical Preparations; Laboratories; Drug Packaging; Product Packaging; Outsourced Services; Commerce; Biological Products; Syringes; Investments; Germany
Published by B3C newswire